Roche uses artificial intelligence for cancer diagnosis
Roche is teaming up with Ibex Medical Analytics and Amazon Web Services in the field of artificial intelligence (AI). The goal is to help pathology labs diagnose cancer. Roche describes the partnership as a step forward in personalized medicine.
Roche headquarters in Basel (image: Roche)
The Basel-based life sciences company Roche is collaborating with Ibex Medical Analytics of Israel and the United States-based Amazon subsidiary Amazon Web Services, according to a statement. The partners are pooling their services to help pathology labs diagnose cancer.
The new solution builds on Roche’s navify Digital Pathology software platform, which now offers AI algorithms from Ibex. The entire system is based on an Amazon Web Services cloud infrastructure.
Laboratories can access the software platform and initially use it for the diagnosis of breast and prostate cancer. The system’s decision support tools are expected to increase turnaround time in laboratories and boost productivity.
AI in personalized medicine in the Basel Area
With the new partnership, Roche says it is expanding its commitment to “improving patient care and advancing personalized healthcare through innovation”.
The Metropolitan Region of the Upper Rhine and the Basel Area offer fertile ground for developments based on the use of AI in personalized medicine. A number of regional initiatives aim to support innovation in this field, for example. The region also promotes knowledge and technology transfer from key stakeholders.